The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction

Introduction Plasminogen activator inhibitor-1 (PAI-1) is linked to thrombosis and endothelial dysfunction in severe COVID-19. The +43 G>A PAI-1 and 4G/5G promoter polymorphism can influence PAI-1 expression. The 4G5G PAI-1 promoter gene polymorphism constitutes the 4G4G, 4G5G, and 5G5G genotypes. However, the impact of PAI-1 polymorphisms on disease severity or endothelial dysfunction remains unclear. Methods Clinical data, sera, and peripheral blood mononuclear cells (PBMCs) of COVID-19 patients were studied. Results Comorbidities and clinical biomarkers did not correlate with genotypes in either polymorphism. However, differences between fibrinolytic factors and interleukin-1β (IL-1β) were identified in genotypes of the 4G/5G but not the 43 G>A PAI polymorphism. Patients with the 4G4G genotype of the 4G/5G polymorphism showed high circulating PAI-1, mainly complexed with plasminogen activators, and low IL-1β and plasmin levels, indicating suppressed fibrinolysis. NFκB was upregulated in PBMCs of COVID-19 patients with the 4G4G genotype. Discussion Mechanistically, IL-1β enhanced PAI-1 expression in 4G4G endothelial cells, preventing the generation of plasmin and cleavage products like angiostatin, soluble uPAR, and VCAM1. We identified inflammation-induced endothelial dysfunction coupled with fibrinolytic system overactivation as a risk factor for patients with the 5G5G genotype.


Introduction
Despite the global efforts in vaccination against the coronavirus disease 2019 (COVID- 19), the loss of lives due to disrupted coagulation/fibrinolysis and inflammatory response remains a significant concern.The fibrinolytic system counterbalances the coagulation cascade with its leading actor tissue factor (1).During fibrinolysis, plasmin degrades fibrin into fibrin degradation products (FDP), including the clinically meaningful D-dimers, which indicate ongoing thrombosis/fibrinolysis.Why certain patients experience more thrombosis or a more robust inflammatory response/cytokine storm syndrome is not fully understood.
PAI-1 biosynthesis can be regulated at the gene level (PAI-1 polymorphisms).The +43G>A polymorphism (rs6092, Ala15Thr) in the first exon of the PAI-1 gene is a missense transition mutation G to A that can change PAI-1 expression.The +43 G polymorphism has been associated with the severity of .
The 4G5G PAI-1 promoter gene polymorphism constitutes a common single-base polymorphism (4 vs. 5 consecutive guanine residues) in the promoter region of the PAI-1 gene, 675 base pairs upstream of the transcriptional start site (16).IL-1b and TGFb modulate the effect of the 4G5G PAI-1 polymorphism on PAI-1 expression.The PAI-1 4G allele produces six times more mRNA than the 5G allele in response to IL-1b.Both 4G and 5G alleles bind a transcriptional activator, such as NFkB, whereas the 5G allele also binds a repressor (17,18).Subjects homozygous for the 4G allele have plasma PAI-1 concentrations ~25% higher than those homozygous for the 5G allele (17,18).In this study, we focused on understanding the role of PAI-1 in inflammation-induced endothelial dysfunction.
Here, we investigated the role of the PAI-1 4G/5G and +43G>A polymorphisms on thrombotic and inflammatory response in Japanese COVID-19 patients.Our exploration revealed no discernible genotypic variations in COVID-19 samples concerning the +43G>A polymorphism, possibly due to our study population's lack of AA genotype.Intriguingly, we pinpointed the 5G5G genotype of the 4G/5G promoter polymorphism as a potential risk factor contributing to inflammation-induced endothelial dysfunction and excessive proteolysis in COVID-19.

High circulating PAI-1 in the complicated phase of the disease
The study included COVID-19 Japanese patients with a positive SARS-CoV-2 test and serum and peripheral blood mononuclear cell (PBMC) samples available at diagnosis.The study comprised 35 patients in the uncomplicated phase and 11 patients in the complicated phase.As reported, most patients presented in the uncomplicated phase of the disease (19).Criteria of the complicated phase included intensive care unit admittance and the need for mechanical ventilation, as listed in detail in the Material and Method section.The old age and comorbidities associated with COVID-19 severity, including heart disease, hypertension, and diabetes at diagnosis, indicated a more severe disease (complicated phase; data not shown).
Circulating PAI-1 levels were higher in the complicated phase of the disease (Figure 1A).Genotyping results were obtained for the PAI-1 4G/5G promoter (rs1799889) and +43G>A polymorphism (+43G>A (rs6092) using the patients' PBMCs.Figure 1B shows an example of the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the PAI-1 polymorphisms.PCR-RFLP results were confirmed by Sanger sequencing (Figure 1C).All patients were genotyped, but no mRNA was recovered in one sample.

COVID-19 comorbidity frequency is similar between genotypes of the 4G/5G PAI-1 promoter and +43G>A polymorphism
Because body weight index (BMI), heart disease, hypertension, and diabetes (20) are comorbidities in COVID-19 but are also linked to the 4G/5G PAI-1 promoter polymorphism, we examined the distribution of these comorbidities among the different genotypes (Table 1).Comorbidities were equally distributed among the 4G/5G PAI-1 promoter and +43G>A polymorphism genotypes (Table 1).
High TroponinT levels in 5G5G of the 4G/ 5G PAI-1 promoter, but not in genotypes of the +43G>A polymorphism Correlation analyses were performed with markers linked to thrombosis (D-dimer, fibrinogen, platelet counts, prothrombin time (PT), or TroponinT), and inflammation (white blood cell counts, lymphopenia with low lymphocyte counts, and C-reactive protein (CRP), interleukin-6 or procalcitonin levels) to identify associations between PAI-1 polymorphisms and thrombosis-or inflammation-associated clinical parameters in COVID-19 patients.No significant associations were found for thrombosis-and inflammation-associated markers between the 4G4G and 5G5G groups and +43G>A polymorphism (Table 2).Levels for Troponin T, a marker associated with disease severity (21) and myocardial infarction, were higher in the 5G5G compared to the 4G5G (p=0.0278) and borderline higher compared to the 4G4G genotype (p=0.0893;Table 2).

Genotype frequencies of two PAI-1 polymorphisms of COVID-19 patients in the uncomplicated and complicated phase
Most patients were in the uncomplicated phase at diagnosis independent of their PAI-1 genotype.When all patients independent of the clinical phase were considered, the allele frequencies for 4G and 5G were identical (Table 3).However, the 5G allele and 5G homozygosity were more frequent in patients in the complicated phase of COVID-19 (Table 3).
The PAI-1 genotype frequencies of the +43G>A polymorphism showed a dominance of the 43GG and 43GA genotypes and no cases of the 43AA genotype in the studied cohort (Table 3).A similar GG and GA genotype frequency distribution was found in patients in the uncomplicated and complicated phase.Our patient cohort did not have patients in the uncomplicated and complicated phase carrying the A allele of +43G>A polymorphism.
Lowest PAI-1 transcripts in PBMCs of COVID-19 patients with the 5G5G genotype Circulating PAI-1 levels in patient blood samples were higher in the complicated than the uncomplicated phase, as measured by ELISA and recently reported (15) (Figure 1A).Polymorphism analysis was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP; Figure 1B) analysis followed by Sanger Sequencing (Figure 1C).PAI-1 transcript levels in PBMCs differed among genotypes for the PAI-1 4G/5G but not the +43G>A polymorphism (Figure 1D).Overall, the highest PAI-1 expression was found among the 4G5G, followed by the 4G4G genotypes, and the lowest transcript levels in the 5G5G genotypes (Figure 1D).These data suggested that the 5G5G genotype is associated with the lowest PAI-1 transcript levels in PBMCs.

4G4G COVID-19 patients show high PAI-1 and low plasmin levels
PAI's effect on plasmin activity, the critical mediator of clot dissolution, is mediated by inhibiting plasminogen activators.Plasminogen concentration in blood is relatively high (around 180 μg/ml), and only a small part is converted to plasmin during fibrinolysis, which is immediately after blood clot dissociation is inhibited by a2-antiplasmin and other minor inhibitors generating the plasmin/inhibitor complexes such as plasmin/a2-antiplasmin (Pm/a2AP; PAP).The plasmin/a2-antiplasmin complex represents plasmin formation in the last 2-8 hours (22).
No differences were evident between genotypes of the +43G>A polymorphism for total PAI-1 protein and activity (based on data reanalyzed from a published data set (15)) and PAP complexes in the uncomplicated phase (Figures 1E, F).Because of the low A allele frequency of the 43G/A polymorphism in our data set, which leads to low patient numbers, especially in the complicated phase, we cannot exclude that this polymorphism might affect PAI-1 or PAP levels.Given these limitations of our sample distribution, we focused further analysis on the 4G/5G polymorphism, which shows the following genotypes: 4G4G, 4G5G, and 5G5G.
In the uncomplicated phase, circulating total PAI-1 protein, active PAI-1, and PAP serum levels were similar between genotypes of the 4G/5G polymorphism (Figures 1E-G).In the complicated phase, there was a trend towards more total PAI-1 protein and active PAI-1 in sera of patients with the 4G4G genotype of the 4G/ 5G polymorphism than the 5G5G genotype (Figures 1E, F).
In the studied cohort, the total PAI-1 antigen level was higher than reported for healthy donors (up to 46 ng/ml according to Mosby's manual of diagnostic and laboratory tests (23)).
Interestingly, the levels of active PAI-1 were below the upper limit of the normal range (32 IU/ml) in most patient samples.Our previous studies demonstrated that Japanese COVID-19 The 4G allele of the PAI-1 promoter is associated with higher PAI-1 transcript and lower plasmin activity in COVID-19 patients.patients have lower risks of thrombo-inflammation than Germans (19), and Japanese healthy controls had lower PAI-1 activity than Europeans (15).The difference in PAI-1 protein level and its activity may explain the low immuno-thrombosis susceptibility of the Japanese population.
PAP levels did not change in the 4G4G group but increased in the 4G5G and 5G5G genotypes in the complicated phase (Figure 1G).These data suggested differences in PAI-1 expression among genotypes of the 4G/5G polymorphism might be linked to severe inflammation (the complicated phase of the disease).However, patient numbers in the complicated phase were low.
Higher NFkB and KLF2 expression in PBMCs of COVID-19 patients with the 4G4G genotype PAI-1 and plasmin levels differed among 4G/5G genotypes, and a trend towards higher total PAI-1 and plasmin levels was observed mainly in the complicated clinical phase with robust inflammatory response and cytokine elevation.These results lead us to speculate that the observed differences in plasmin activation between the 4G4G versus 5G5G patients (PAI-1 4G/5G polymorphism) are linked to inflammation (18).The 4G and 5G alleles bind a transcription factor like NFkB.The 5G allele, in addition, can bind a repressor, resulting in a dampened NFkB response and lower PAI-1 levels (17,18).High NFkB expression was found in COVID-19 patient's PBMCs of the 4G4G and 4G5G but not 5G5G genotypes with significant differences between 4G4G and 5G5G groups (Figure 2A).The Krüppel-like factor 2 (KLF2) transcription factor modulates PAI-1 expression in ECs (24).KLF2 expression was higher in PBMCs of the 4G4G than in the 5G5G genotypes (Figure 2B).Spearman analysis revealed NFkB, but not KLF2, correlated with PAI-1 expression in PBMCs with the 4G4G and 4G5G but not the 5G5G genotypes (Figure 2C).These data indicated the proinflammatory transcription factor NFkB positively associated with the 4G4G and 4G5G, but not the 5G5G genotypes.
TGFb expression was higher in 4G4G than in 4G5G or 5G5G genotype PBMCs (Figure 2G).A similar cytokine and transcription factor expression trend was found after subgrouping cytokine expression data according to the patient's clinical phase (data not shown).Despite low proTGFb serum levels in 4G4G genotypes (Figure 2H), active TGFb serum levels were similar between the 4G/ 5G genotypes (Figure 2I).Although TGFb expression was higher in 4G4G PBMCs, active TGFb1, whose generation requires plasmin activation, was not different.Despite similar transcript levels in PBMCs, circulating IL-1b levels were lowest in the 4G4G and highest in the 5G5G genotype and different between the genotypes (Figure 2J).No transcription and cytokine expression differences were seen in the +43 G genotypes (data not shown).These results indicated that COVID-19 patients with the 4G4G genotype had the highest NFkB expression in PBMCs and the lowest circulating IL-1b levels.

Shutdown of fibrinolysis in IL-1bstimulated 4G4G ECs
The data on more patients in the 5G5G group with higher Troponin T and being found in the complicated phase might hint at endothelial dysfunction during COVID-19 infection.Endothelial dysfunction has been reported in 25).Infectioninduced IL-1b activation contributes to the impaired endothelial barrier function and procoagulant/anti-fibrinolytic shift in the endothelium (26).Previous studies have shown that the 4G/5G locus present in the PAI-1 promoter is required for IL-1b-induced PAI-1 gene expression in HepG2 cells (18).To better understand whether IL-1b can activate PAI-1 gene expression through the 4G or 5G locus in endothelial cells (ECs), we examined the effect of IL-1b on the PAI-1 4G or 5G promoter transcriptional activity using the reporter vector pGL4.1-[luc2] where the 4G or 5G promotor sequences were placed upstream of the luciferase gene.Transient transfection of these reporters into human umbilical vein endothelial cells (HUVEC) cells resulted in similar basic transcription activities, which were increased in response to recombinant IL-1b after overnight incubation in HUVEC cells transfected with the 4G4G, but not the 5G5G PAI-1 promoter plasmid (Figure 3A).These data suggest that the 4G4G region of the PAI-1 promoter is required for IL-1b-mediated PAI-1 induction.
To further investigate the influence of the 4G5G polymorphism on IL-1b-mediated fibrinolysis-associated factor production, primary ECs (human lung microvascular endothelial cells and and HUVECs) with known genotypes (two EC sources per genotype) were incubated with recombinant IL-1b overnight.
IL-1b treatment enhanced PAI-1 and uPA and downregulated tPA expression in 4G4G and 4G5G but not 5G5G genotypes (Figures 3B-D).PAI-1 and tPA, but not uPA expression, differed between 4G4G and 5G5G genotypes.Given that the primary plasminogen activator produced ECs is tPA, these data indicated that IL-1b in the 4G4G genotype suppresses fibrinolytic factor expression in ECs, indicative of a fibrinolytic shutdown.

Protease cleavage products in supernatants of IL-1b−stimulated 5G5G ECs
More plasmin (PAP) was found in IL-1b-stimulated EC cultures of the 5G5G genotype than in the 4G4G genotype, indicating enhanced plasmin proteolytic activity (Figures 3H, I).
K1-3 (38 kDa) can be generated by neutrophil elastase (31) and MMP7.Neutrophil elastase is mainly expressed in neutrophils and not EC.We, therefore, analyzed MMP7 expression in culture supernatants.MMP7 protein was induced in IL-1b-stimulated EC cultures of 4G5G cells (data not shown).In summary, PAI-1 elevation after IL-1b did not occur in the 5G5G ECs, establishing a plasmin-mediated proteolytic status/niche.
To confirm our in vitro observation of IL-1b stimulation of HUVEC cells, we analyzed s-uPAR and its D2D3 fragments in patient sera.The analysis of circulating total s-uPAR (D1-D3) in COVID-19 patients as determined by ELISA showed no significant difference between genotypes (Figure 4H).However, D2D3 fragment serum levels were higher in 4G5G compared to 4G4G genotypes (Figure 4I).
Vascular cell adhesion molecule 1 (VCAM1) is an adhesion molecule expressed on ECs that controls cell adhesion and the inflammatory response during SARS-CoV-2 infection (35).Like s-uPAR, proteases can release VCAM1 into circulation as soluble VCAM1.In line with protease activation ("proteolytic niche"), more sVCAM1 was detected in the sera of patients with the 5G5G than in the 4G4G genotype (Figure 4J).

Discussion
Despite widespread vaccination efforts globally, COVID-19 continues to claim lives, partly due to dysregulated coagulation/ fibrinolysis and inflammatory responses (36).Analyzing PAI-1 polymorphism as a genetic factor that regulates fibrinolysis could predict life-threatening thrombosis, which could save lives.
We show that the 4G/5G PAI-1 promoter polymorphism is a critical determinant of fibrinolytic and proteolytic activity on EC surfaces after COVID-19 infection and is linked to IL-1b increases.Still, when IL-1b is low or absent, the 4G/5G PAI-1 promoter polymorphism does not influence fibrinolytic and proteolytic activity.
Our data suggest that the 4G/5G PAI-1 promoter polymorphism controls PAI-1 induction and the fibrinolytic and proteolytic response under inflammatory pressure in ECs.The 4G4G genotype is endowed with impaired fibrinolytic and proteolytic activity due to IL-1b-mediated PAI-1 upregulation, resulting in an increased thrombotic risk (Figure 4K).
We tested the +43 G>A PAI-1 polymorphism and 4G/5G PAI-1 promoter polymorphism in Japanese COVID-19 patients.Our data on the Japanese COVID-19 patients demonstratedin contrast to the study with Mexican COVID-19 patients (37)that total PAI-1 and plasmin levels differed between genotypes of the 4G/5G, but not the +43 G>A PAI-1 polymorphism in COVID-19 patients.Japanese COVID-19 patients with the 4G4G genotype had higher PAI-1 and lower plasmin levels, establishing a fibrinolytic shutdown and prothrombotic condition.In support of our findings, the 4G4G genotype in a large meta-analysis was associated with an increased venous thromboembolism risk among Asia populations (38).
We did not further analyze the +43G>A polymorphism as we did not find a single patient with the AA genotype.Our data are consistent with a study cohort of 227 healthy Asian women, where no AA genotype was detected (39), supporting our findings that the AA genotype is extremely rare in Asians.
We confirm reports by others (18) showing PAI-1 expression was independent of the patient's genotype for the 4G/5G polymorphism in the uncomplicated phase.The differential response between genotypes for the 4G/5G polymorphism became apparent in patients with high IL-1b levels, a typical cytokine that indicates severe inflammation and an inflammatory response (40).IL-1b is a critical switch on ECs to control local fibrinolysis mediated by the 4G/5G PAI-1 polymorphism.Mechanistically, IL-1b enhanced PAI-1 expression, promoted PAI-1 complex formation with tPA or uPA, and reduced tPA expression, establishing fibrinolytic shutdown in 4G4G ECs.The lack of PAI-1 response and unchanged tPA and uPA expression after IL-1b stimulation in 5G5G ECs creates a hyperfibrinolytic state with plasmin activation (proteolytic niche) (Figure 4M).This proteolytic storm enabled the cleavage of membrane proteins like uPAR and circulating proteins like Plg, leading to enhanced s-uPAR and Plg fragment K1-3 (angiostatin) formation.
Why this studyusing Japanese patient samplesbut not other studies could identify the 4G/5G PAI-1 polymorphism as critical for the fibrinolytic response in COVID-19 patients, it is essential to see the differences in the study groups.First, compared to other Western countries, the 4G4G genotype is more frequent in Japanese (41), making differences between the 4G4G and 5G5G genotypes easier to detect.Second, obesity is not so prevalent in Japan, although it is a pandemic worldwide.Metabolic syndromeassociated diseases like adiposity, diabetes, and hypertension, even without COVID-19, can establish chronic low-level inflammation that alters PAI-1 expression (37, 42, 43).These two conditions possibly contributed to identifying links between COVID-19 and the 4G/5G PAI-1 polymorphism.In the clinical samples of COVID-19 patients, we cannot rule out that subjects' comorbidity profiles might modulate PAI-1 expression.A recent meta-analysis showed that the PAI-1 4G/5G polymorphism was associated with coronary artery disease risk (44).We found higher Troponin T levelsassociated with heart diseasein 5G5G COVID-19 patients.
Even though plasma PAI-1 circulates at low levels (5-50ng/ml), it mainly adopts the active conformation.In our study the total antigen level of PAI-1 was higher in COVID-19 patients compared to the normal range (23).Surprisingly, PAI-1 activity levels were below the known upper limits of the normal range, suggesting that most PAI-1 is inactive.
Our previous studies demonstrated that Japanese COVID-19 patients are less likely to develop thrombo-inflammation than Germans.Japanese healthy controls have lower PAI-1 activity than Europeans (15).The differences in PAI-1 protein level and activity may explain the low immune-thrombosis susceptibility in the Japanese population.
We found that COVID-19 patients with the 4G4G genotype had high PAI-1 transcript levels in PBMCs and low circulating plasmin and IL-1b or proTGFb levels, indicating a mild inflammatory response.We found a strong positive correlation of NFkB with the 4G4G and 4G5G genotypes, which might have contributed to the high TGFb expression levels in 4G4G patients.While the higher TGFb transcripts might be linked to higher NFkB expression in 4G4G PBMCs, it is unclear why low circulating proTGFb was found in this genotype.Active TGFb was similar between 4G5G genotypes, making its influence on PAI-1 expression less likely.The lack of plasmin and possibly other protease generation in the 4G4G genotype may contribute to these changes.Other growth factors like TNFa (data not shown) might also contribute to changes in PAI-1 expression but might be independent of the 4G/5G PAI-1 polymorphism.
The central position of IL-1b was demonstrated in cultured ECs.Using Firefly luciferase reporter plasmid containing the 4G site in the proximal PAI-1 promoter, our data indicate that IL-1b enhanced PAI-1 expression in ECs with the 4G4G genotype, similar to earlier studies using HEPG2 cells (18).
The IL-1b-induced fibrinolytic shutdown in the 4G4G genotype was further aggravated by IL-1's impairment of tPA expression in ECs.PAI-1 upregulation and tPA downregulation in the 4G4G after IL-1b caused "fibrinolytic EC paralysis." During COVID-19, the transcription factor KLF2, a master regulator of vascular homeostasis, is downregulated in ECs (45) and was associated with COVID-19-associated EC dysfunction (24).We confirm reports by others that IL-1b decreased KLF2 gene expression in ECs, with the most robust reduction observed in ECs with the 4G4G but not the 5G5G genotype (Figure 4D).
It was speculated that drugs like atorvastatin that can induce KLF2 expression would improve EC functions of COVID-19damaged ECs due to their anti-inflammatory and anti-thrombotic functions.Our data indicate that the most potent suppression of KLF2 was observed in ECs with 4G4G.Therefore, patients with this genotype might profit from atorvastatin.KLF2 can suppress the transcriptional activity of NFkB (46) and inhibit monocyte activation (47), resulting in an anti-inflammatory status.This reverse expression pattern between the transcription factors was not observed in COVID-19 PBMCs.Spearman analysis indicated that NFkB, not KLF2, was linked to PAI-1 expression.The transcriptional activity of NFkB and KLF2 activity is antagonistically regulated in HUVECs (48).In ECs, the induction of proinflammatory cytokines reduces the expression of KLF2.It is important to note that the activities of NFkB and KLF2 are regulated at the transcriptional level and can also be increased at the protein level (48).
Like PAI-1, IL-1 is implicated in the pathogenesis of inflammatory diseases, including arthritis, atherosclerosis, and inflammatory bowel disease, where anti-IL-1 treatments are considered (50).Although IL-1 is regarded as a critical driver of hyperinflammation and cytokine storm (51), studies to block IL-1 (Anakinra, the monoclonal antibody (mAb) canakinumab, or the soluble IL-1 trap rilonacept) were shut down early as the treatment groups did not show clinical improvements.Results of Anakinra (an Ab against the IL-1 receptor alpha) on the improvement of acute respiratory distress syndrome in COVID-19 patients vary from showing no effect (52) to being effective in a subgroup of patients with increased soluble uPAR (s-uPAR) levels (32,53).We are the first to report a link between s-uPAR release from IL-1-stimulated ECs or sera from COVID-19 patients in the complicated phase.Circulating IL-1b and s-uPAR levels were high in the 5G5G COVID-19 patient group.Further studies will be necessary to determine whether COVID-19 patients carrying the 5G5G, but not 4G4G genotype, or patients with other IL-1b-related inflammatory diseases might benefit from drugs blocking IL-1 signaling.
In conclusion, combining clinical evidence and in vitro studies, we identify the 5G5G genotype of the 4G5G polymorphism as a risk factor for inflammation-induced endothelial dysfunction combined with the overactivation of the fibrinolytic system.

Study population and data collection
The inclusion criteria were adult patients older than 18 years, in-and outpatients, patients admitted to Juntendo University with a positive PCR or rapid antigen test for SARS-CoV-2, availability of basic medical information, including ethnicity, patient history, initial blood laboratory data, and outcome data.
The Japanese study population included adults admitted to Juntendo University.All study participants recruited between March 2020 and February 2021 gave informed consent to anonymize their clinical data.The inclusion criteria for COVID-19 cases, clinical phase inclusion criteria, and comorbidity criteria were described earlier (19).We used the criteria to determine the complicated COVID-19 phase according to LEOSS criteria (19): need for new oxygen supplementation due to clinical deterioration, oxygen saturation (SO2) at room air < 90%, partial pressure of oxygen (PaO2) at room air < 70 mmHg, clinically meaningful increase of oxygen supplementation compared to prior oxygen home therapy, an increase of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 × ULN (upper limit of normal), new cardiac arrhythmia, new pericardial effusion > 1 cm or new heart failure with pulmonary edema, congestive hepatopathy or peripheral edema, catecholamine therapy, life-threatening cardiac arrhythmia, liver failure with an INR > 3.5 (Quick < 50%), a qSOFA score of ≥ 2 or acute renal failure with the need of dialysis.
Opt-out samples of COVID-19 subjects were stored at the Biobank of Juntendo University after obtaining informed consent.Peripheral blood mononuclear cells (PBMCs) and sera were collected and stored from randomly chosen patients.After removing duplicates, missing diagnosis information, and dead patients, 46 COVID-19 patients at diagnosis with clinical data, stored blood sera, and PBMC cells were available for analysis.Clinical data of the selected patients and protein sample data were part of a more extensive study published in (19).We assessed matching quality using standardized mean differences for outcome analysis (biomarker analysis).

Quantitative PCR
RNA isolation and cDNA extraction have been described previously (54).The qPCR determined the mRNA expression levels using the QuantStudio 3 real-time PCR system (Applied Biosystems, USA) with the TB Green Premix Ex Taq II (TaKaRa, #RR820A).Gene expression was determined by comparative SYBR green qPCR using an Applied Biosystems StepOnePlus Real-time qPCR.We calculated the relative mRNA expression for all genes and mRNAs using the 2-DDCt method.Each qPCR experiment was performed in triplicate and independently repeated two times.Unless otherwise mentioned, gene expression was normalized for all qPCR results to b-actin mRNA expression.The respective forward and reverse primers are listed below: enotype assessment using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis Genomic DNA was extracted from patients' PBMCs, cultured HUVECs, and amplified by PCR using gene-specific primers [protocol modified from (55)].The PAI-1 -675 4G > 5G (rs1799889) polymorphism was detected by PCR-RFLP analysis using forward (5′-CCA ACA GAG GAC TCT TGG TC-3′) and reverse (5′-CAC AGA GAG AGT CTG GCC ACG-3′) primers.The 99-bp product was digested with 1 U BslI for one hour at 55°C.A restriction fragment of 99-bp represented the 4G4G genotype; fragments of 99 bp, 77 bp, and 22 bp represented the 4G5G genotype; and the 77-bp and 22-bp products represented the 5G5G genotype.
Genotyping results were confirmed by sequencing 30% of randomly selected samples, followed by DNA sequencing, to validate the RFLP findings at FASMAC, Japan.The concordance of the quality control samples was 100%.

Western blot analysis in EC culture supernatants
Supernatant samples were centrifuged at 5000 g to remove fibrin and diluted 1:4 in 2x Laemmli sample buffer.Samples (5 μl) were applied on 8% acrylamide gel transferred to a PVDF membrane (Millipore, Immobilon).Then membranes were probed with one of the following primary Abs: uPAR rabbit polyclonal Abs (1 ug/ml (56); Plg rabbit polyclonal Abs (0,5 ug/ ml, (57); a2-antiplasmin rabbit polyclonal antibodies (1:1000, #sc73659, Santa Cruz, Dallas, USA).Membranes were stained with secondary Ab conjugated with goat anti-rabbit polyclonal HRP-conjugated, Santa Cruz #sc2004, working dilution working dilution 1:8000) and secondary rabbit anti-hamster HRPconjugated (1:2000, #ab5745, Abcam, Cambridge, UK).Membranes were developed with the ECL Prime Western blotting reagent (Amersham #RPN2236), and images were taken using the image analyzer ImageQuant LAS 4000 (GE Healthcare).Quantification of the protein bands was performed with ImageJ software.Due to patient sample scarcity, western blot data for IL-1b, uPAR (D2D3), and sVCAM1 in COVID-19 patients were reanalyzed from a data set published on the same patients but without the knowledge of genotypes (15).These data were reanalyzed and sorted according to the patients' genotypes.
Because Plg is present in the culture medium's serum, the effects of IL-1b treatment were compared to the respective untreated control supernatants.
Western blots of patients' serum samples were normalized to the volume of loaded serum, and all the serum markers were measured by other methods (ELISA, activity assay, and clinical data).
HUVECs/HMVECs were seeded at a density of 1x10 5 per well using 6-well plates for growth factor stimulation.Cells were kept untreated overnight to ensure cell adherence.Cells were treated with or without recombinant human IL-1b (Peprotech #0606B95).IL-1b was added to cultures at a concentration of 10 ng/ml.After a 24-hour culture period, cells were collected and subjected to RNA isolation.Supernatants of cultures were collected and stored at -80°C until usage in Western blotting.
DNA fragments were then subcloned into the Firefly luciferase reporter plasmid pGL4.1[luc2]using NEBuilder HiFi DNA Assembly Cloning Kit (New England Biolabs, USA).
Analysis of transcriptional activation of the 4G/5G PAI-1 promoter using a reporter assay Twenty-four hours after transfection of HUVECs, human recombinant IL-1b (#200-01B, Peprotech, USA) was added at a final 10 ng/ml concentration.Reporter activities were measured 48 h post-transfection/24 h post-IL-1b-stimulation using a dualluciferase reporter assay system (Promega, USA).Luciferase activity was normalized to Renilla values to control for differences in transfection efficiency and then standardized to the empty vector control.The values are expressed as means ± SEM.

Clinical data statistics
We compared the characteristics of SARS-CoV-2-positive Japanese patients and included some analysis data from healthy donors.We presented continuous and categorical variables as median and n (%).Before predicting the patients' clinical phases, we organized comorbidities and biomarkers as categorical variables (yes versus no).First, we calculated a contingency matrix by counting the frequencies of patients in different clinical phases and specific variable intervals.Then, the statistical dependence test was performed based on the number of intervals and the obtained frequencies.We considered Fisher's exact test if the contingency table had a 2 × 2 shape (two-variable intervals).We chose the appropriate test when tables with more than two intervals were analyzed, i.e., we executed the X 2 test when the frequencies in each cell were at least five.However, in the case of analyzing tables with more intervals and some frequencies below five, Fischer's exact test simulation was performed using the Monte Carlo approach, available in the R statistical package 3.6.3.This package was used to calculate the Pearson correlation test of the numerical values for all biomarkers.We attributed the mean value for patients with missing data for the BMI.p < 0.05 was regarded as significant.
A multivariate odds ratio (OR) and corresponding confidence intervals were presented using the R program for each variable included in regression models.The OR for the 4G/5G genotypes was calculated using the 5G5G genotype as the reference category.The OR for the GG genotypes was estimated using the GA genotype as the reference category.A two-tailed P value < 0.05 was considered statistically significant.

Sample analysis statistic
All experiments were performed at least three times.P values < 0.05 were considered statistically significant.Data are presented as mean ± SEM.
Outliers were checked using the ROUT test (Q=0.5%)and removed before group comparison.All data, including outliers, were presented in the actual figure panels.Data distributions were tested for normality using the Shapiro-Wilk normality test.Student's t-tests (two groups) or ANOVAs (more than two groups) were applied to normally distributed data to evaluate the statistical significance of differences between groups with the Welch test for comparison of groups with heterogeneous variances.A Mann-Whitney (two groups) or a Kruskal-Wallis test (more than two groups) was applied for non-normally distributed data.Spearman's correlation test was used to test the association between two variables.
The linear correlation test and determination of the Spearman coefficient were applied to estimate the association between tested variables.
Science, the University of Tokyo (KH, BH), The Uehara Memorial Foundation (BH), Taiki Life Welfare Foundation (KH), Heiwa Nakajima foundation grant (BH), and a grant from Institute for Environmental & Gender-specific Medicine, Juntendo University (BH).

FIGURE 1
FIGURE 1 (A) PAI-1 levels as measured by ELISA in the study cohort (n=43).(B) Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analyses of all patient samples showed allele-specific fragments after restriction enzyme treatment.(C) Examples of Sanger Sequencing for confirmation of the identified PAI-1 4G/5G rs1799889 and +43G>A (rs6092) polymorphisms.In the study group, we did not find the 43AA genotype.Therefore, no data were available (not found, N/F) for this genotype in panels (D-G).(D) Fold change in PAI-1 expression in peripheral mononuclear cells (PBMCs) of COVID-19 patients sorted by genotype (n=42).The expression of indicated genes is normalized to the endogenous reference b-actin and presented as a relative fold change to the expression in 4G/4G groups according to the comparative Ct method (2−DDCt).Experiments were repeated twice with samples run in triplicates each.(E) Circulating total PAI-1 protein sorted according to genotypes (data set is the same as in panel (A).(F) PAI-1 activity after sorting in genotypes as determined by ELISA [reanalysis of original data published (15)].(G) Serum plasmin/a2-antiplasmin complex levels by ELISA.Dots in each panel represent data from one patient sample.N.F., not found, N/A, not available.Data represent mean ± SEM with p values from unpaired Student's t-test or the Mann-Whitney test.# p<0.05; * p<0.05; ** p<0.01; *** <0.005; n/s, not significant.

FIGURE 2
FIGURE 2 Circulating proTGFb and IL-1b protein but not cytokine transcripts in PBMC of COVID-19 patients were higher in 5G5G patients.NFkB (A) and KLF2 (B) expression in PBMCs of COVID-19 patients were sorted for genotypes of the 4G5G PAI-1 promoter polymorphism.(C) Heat map of Spearman's correlation coefficient between 4G5G PAI-1 polymorphism coefficient and the transcription factors NFkB and KLF2 in COVID-19 patients.The correlation coefficients are represented in the white-brown color intensity change (left panel), as shown in the color bar.P-values of the parameter correlations are given using white-green color coding (right panel).P values were statistically significant (p<0.05) with 95% CIs for each correlation coefficient.(D-G) Fold change in IFNg (D), IL-6 (E), IL-1b (F), and TGFb (G), expression in PBMCs of COVID-19 patients sorted for genotypes of 4G5G PAI-1 promoter polymorphism.The expression of the indicated genes is normalized to the endogenous reference b-actin and presented as a relative fold change to expression in 4G/4G groups according to the comparative Ct method (2−DDCt).Gene expression data: Experiments were repeated twice using at least 2-3 samples per test group.(H, I) Analysis of proTGFb (H) by western blotting, active TGFb by ELISA (I), and IL-1b by western blotting (J) in sera of COVID-19 patients.(H, I) Western data are quantified by band intensity data normalized to a sample from a healthy donor and are the reanalysis of original data published in (15).Data represent mean ± SEM.Depending on the sample normality, p values were determined using the unpaired Student's t-test or the Mann-Whitney test.* p<0.05; ** p<0.01; *** <0.005; n/s, not significant.

FIGURE 3 IL
FIGURE 3 IL-1b establishes an anti-fibrinolytic gene expression profile in 4G4G primary endothelial cells (ECs).(A) Transcriptional activation of the human PAI-1 promoter by recIL-1b.HUVEC cells were transiently transfected with the PAI-1 4G and 5G luciferase reporter plasmids.Cells were treated with or without IL-1b for 24 hours before lysis.Firefly luciferase activity was normalized to Renilla luciferase activity and is expressed as fold change to controls.Data shown are the mean ± SEM of triplicates from a representative experiment (n=3/group).(B-G) Fold change in PAI-1 (B), tPA (C), and uPA (D), KLF2 (E), NFkB (F), and TGFb (G) expression in cultured 4G4G, 4G5G, or 5G5G ECs stimulated with rec IL-1b (two independent experiments using two different cell origins per genotype were performed; data shown are from one experiment; n=4/group).The expression of the indicated genes is normalized to the endogenous reference b-actin and presented as a relative fold change to expression in the control expression of each genotype according to the comparative Ct method (2−DDCt).(H) Immunoblot of plasmin/a2-antiplasmin complex (PAP) in an equal volume of supernatants of EC cultures.(I) Band intensity quantified of the G blot, whereby each recIL-1b sample was normalized to its control samples.(J-L) A representative immunoblot of Plg using supernatants from cultures treated with or without (control) IL-1b showed angiostatin fragments (J) after loading an equal volume of supernatants from EC cultures.Band intensity quantified of the I blot, whereby each recIL-1b sample was normalized to its control samples, showing the Plg cleavage fragment angiostatin at 38 kDa (K) and 50 kDa (L).All western blots were performed at least twice with similar results.# p<0.05; ## p<0.01; * p<0.05; ** p<0.01; *** p<0.005; n/s, not significant.In vitro data were presented as box plots to discriminate in vivo data from the following in vitro data.All experiments were done in triplicate, and two cell lines for each genotype were used.

FIGURE 4 The
FIGURE 4The 4G4G genotype associates with high tPA/PAI-1 complexes and lower proteolytic fragments angiostatin 38kDa, s-uPAR, and sVACM1 in COVID-19 patient sera and rec IL-1b stimulated ECs.(A, B) ECs with known 4G5G PAI-1 promoter genotypes were cultured overnight with IL-1b.A representative immunoblot of uPA (A) and uPA/PAI-1 complex (B) and band intensity quantification after loading an equal volume of supernatants from EC cultures.(C) Free/uncomplexed uPA [(C); a reanalysis of original data published in (15)] after band quantification of an immunoblot in COVID-19 sera.Serum uPA/PAI-1 complex (D) levels measured by ELISA in COVID-19 patients with indicated genotypes.(E, F) Free/uncomplexed tPA (E) and tPA/PAI-1 complex (F) levels were determined by western blotting [data were analyzed according to genotypes: original data in (15)].(G) Supernatants collected from rec IL-1b-and carrier/control-treated EC cultures were analyzed by western blot analysis for the D2D3 fragment of s-uPAR.Band intensity was quantified by normalizing each rec IL-1b sample to its control sample.(H) Total s-uPAR (D1-D3) in COVID-19 sera as determined by ELISA.(I, J) Western blot analysis for s-uPAR/D2D3 (I) and sVCAM (J) in sera of COVID-19 patients sorted according to their genotypes for the 4G5G PAI-1 Promoter polymorphism [reanalysis of original data in (15)].(K) Proposed model for the influence of the 4G5G polymorphism during SARS-CoV-2 infection with a robust inflammatory response: Higher IL-1b was found in the circulation of COVID-19 patients with the 5G5G genotype.IL-1b upregulates PAI-1 and NFkB expression in ECs with the 4G4G but not the 5G5G genotype.Cytokine (IL-1b)-induced PAI-1 forms complexes with its activators tPA and uPA, especially in the 4G4G genotype, resulting in impaired uPA and tPA-driven plasmin generation in the 4G4G genotype, ultimately generating a proteolytic shutdown.In ECs, IL-1b downregulates KLF2 expression, possibly to counterbalance PAI-1 upregulation.This process is the opposite in 5G5G EC.Low PAI-1 levels after IL-1b stimulation contribute to high active plasmin that further fuels IL-1b and TGFb generation and establishes a proteolytic niche.In vitro data were presented as box plots to discriminate in vivo data from the following in vitro data.All experiments were done in triplicate, and two cell lines for each genotype were used.NFkB, Nuclear factor kappa-light-chain-enhancer of activated B cells; KLF2, Krüppel-like factor 2; PBMC, peripheral blood mononuclear cells; interleukin-1 b, IL-1b, TGF b, transforming growth factor-b; MMP, matrix metalloproteinase.Data represent mean ± SEM.Depending on the sample normality, p values were determined using the unpaired Student's t-test or the Mann-Whitney test.* p<0.05; **p<0.01;*** p<0.001; n/s, not significant.

TABLE 1
Univariate analysis of baseline clinical parameters among Japanese COVID-19 patients at diagnosis.

TABLE 3
Distribution of PAI-1 genotype frequencies in COVID-19 patients in the uncomplicated and complicated phase.

TABLE 3 Continued
Patients showing one specified genotype were enrolled in the yes group.Data are n (%).The odds ratio (OR) measures the relative risk of COVID-19 infection between subjects with the 4G/4G genotype and subjects with the 4G/5G or 5G/5G genotype.